JLE

Médecine de la Reproduction

MENU

Polycystic ovary syndrome: new guidelines Volume 23, issue 3, Juillet-Août-Septembre 2021

Figures


  • Figure 1

  • Figure 2

  • Figure 3

Tables

Author
AP-HP, hôpitaux universitaires Pitié-Salpêtrière, service d’endocrinologie et médecine de la reproduction et Centre de référence des maladies endocriniennes rares de la croissance, Sorbonne Université, 75013 Paris, France
* Tirés à part

Polycystic ovary syndrome (PCOS) is the most common ovarian disorder associated with androgen excess in women, which justifies the growing interest of endocrinologists. This syndrome leads to clinical hyperandrogenism and/or a biological dysovulation and infertility. Its diagnosis is based on consensual diagnostic criteria, but which have change recently with new ESHRE guidelines. In addition, the relevant impact of metabolic issues, specifically insulin resistance and obesity, on the pathogenesis of PCOS, and the susceptibility to develop earlier than expected glucose intolerance states, including type 2 diabetes, has supported the notion that these aspects should be considered when planning potential therapeutic strategies.